Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, ...

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro was about as good at preventing heart attacks and strokes as its older ...

Eli Lilly’s blockbuster diabetes drug Mounjaro matched the ability of an older treatment to prevent major heart complications ...

The lawsuits have been filed over the past two weeks in Marion Superior Court against Eli Lilly and Co., which says its drugs ...

But Eli Lilly's supply woes began to ease earlier this year, and the Food and Drug Administration removed tirzepatide, the active ingredient in Mounjaro and Zepbound, from its shortage list.

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as supply of both medicines has largely recovered ...